Efficacy of OTC analgesics

Authors


  • Disclosures RAM has received lecture fees from or consulted for various pharmaceutical companies (including Reckitt Benckiser) for activities related to analgesics and other healthcare interventions, and received research support from charities, government and industry sources at various times. CD declares no conflict of interest.

R. Andrew Moore, Pain Research and Nuffield Division of Anaesthetics, University of Oxford, The Churchill, Headington, Oxford OX3 7LJ, UK
Tel.: +44 1865 225674
Fax: +44 1865 225402
Email: andrew.moore@ndcn.ox.ac.uk

Summary

For many ‘over-the-counter’ (OTC) analgesics, there is little information available about their relative efficacy. We have examined information available in a series of Cochrane reviews of single doses of analgesic drugs in acute pain and migraine for its relevance for analgesic products commonly available without prescription, at doses generally equivalent to two tablets. Pain following third molar extraction was used as a homogeneous acute pain model; with the outcome of at least 50% maximum pain relief over 6 h. For many OTC drugs, there was no information available. For some OTC drugs, there was at least some information available either for the marketed product itself, or from studies that used the same doses of drug or drugs. For acute pain, data from third molar extraction studies showed that several OTC products were highly efficacious, principally non-steroidal anti-inflammatory drugs (ibuprofen, naproxen, diclofenac) and combination products based on ibuprofen; aspirin and paracetamol-based products were less efficacious. Fixed-dose combinations, especially those with ibuprofen, provided high levels of analgesia. For migraine headache, the outcome used was pain initially moderate or severe becoming no worse than mild pain (no pain, mild pain) at 2 h. Single-dose ibuprofen 400 mg was better than aspirin and paracetamol.

Ancillary